Adil Daud, MD, on the Importance of Testing Patients with Melanoma for BRAF Mutations

Video

Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.

Adil Daud, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center discussed with CancerNetwork the use of next-generation sequencing to not only spot common BRAF mutations but find rarer mutations in patients with melanoma.

Transcription:

It’s an extremely important subject, and in the past people would use the specific BRAF test and that’s what we did too. But I’d say in the last 2-3 years, most centers in the US have switched to using next-generation sequencing, which has the advantage that you can see the BRAF mutation but you can also see some of the uncommon BRAF mutations like V600K, V600D which it’s about 10% of all BRAF mutations are non-V600E which is the one that’s detected by the BRAF test. But then also you can recognize things like NRAS mutations C-KIT mutations and some of the fusions like the ROS1 fusion, ALK fusion that are rare, but are seen sometimes especially in younger people with melanoma or in melanoma that arises in the achiral extremities, those types of melanomas. Also, for uveal melanoma, next gen sequencing can spot GNAQ, GNA11 mutations, BAP1 loss, which straight forward V600E tests won’t do.

I think the downside of NGS is that it takes 2-3 weeks to get the results back and sometimes you really need to get somebody started as soon as possible. I think it’s reasonable in my opinion to start with immunotherapy, given what we’ve just discussed, while you’re waiting for your NGS results and then when you get your NGS results you could decide whether it makes sense to do target therapy or not.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content